Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-095467
Filing Date
2024-08-12
Accepted
2024-08-12 16:20:20
Documents
50
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q oric-20240630.htm   iXBRL 10-Q 1989597
2 EX-31.1 oric-ex31_1.htm EX-31.1 16172
3 EX-31.2 oric-ex31_2.htm EX-31.2 16175
4 EX-32.1 oric-ex32_1.htm EX-32.1 8898
5 EX-32.2 oric-ex32_2.htm EX-32.2 8884
  Complete submission text file 0000950170-24-095467.txt   6347948

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT oric-20240630.xsd EX-101.SCH 804504
53 EXTRACTED XBRL INSTANCE DOCUMENT oric-20240630_htm.xml XML 939808
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

EIN.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39269 | Film No.: 241197075
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)